Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India

Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company has launched Chlorantraniliprole (CTPR) 18.5% SC under the Brand Name of NATGEN in the Indian Market.

NATCO is the 1st Company in India to have received its registration approval given by the Central Insecticide Board & Registration Committee (CIB&RC), recorded in its Minutes of the 425th Meeting held on January 25th, 2021, for the indigenous manufacture of Chlorantraniliprole (CTPR) Technical 93.00% w/w min. under Section 9(3).

CTPR technical is formulated into broadspectrum insecticides used across a wide range of crops for pest management.

Read also: Delhi HC nod to Natco Pharma for the launch of Chlorantraniliprole and its formulations

NATCO estimates the current market size of CTPR-containing products in India to be over INR 2000 crores.

Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing, and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.

Read also: Natco partner bags USFDA nod for Cabazitaxel Intravenous Powder

Natco sells its FDF products in the United States, India, Europe, and the rest of the world ("RoW"). In the API segment, the company has capabilities to develop and manufacture products with multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides.

The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Read also: Natco Pharma secures USFDA nod for Trabectedin for Injection